CRISPR Therapeutics (CRSP)
Develops genome-editing medicines across blood disorders, liver targets, autoimmune disease, and diabetes.
$56.78
vs last close−2.25 (−3.81%)
Something off on this page? Send us feedback.
Next report
Nov 9, 26
estimated · in 47 days
EPS estimate
−$1.06
Revenue estimate
$14.6M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.44−$1.58−$2.40−$1.17−$1.37−$1.28−$0.94Pending
Estimate−$1.15−$1.27−$1.47−$1.26−$1.15−$1.19−$1.19−$1.06
Surprise+61.7%−24.4%−63.3%+7.1%−19.1%−7.6%+21.0%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$35.0M$865.0K$892.0K$889.0K$864.0K$1.5M$10.2MPending
Estimate$8.1M$6.0M$6.1M$9.1M$4.7M$6.1M$7.4M$14.6M
Surprise+334.5%−85.5%−85.5%−90.3%−81.7%−76.0%+36.7%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.74 | — | — |
| Sep 2027 | −$0.76 | — | — |
| Jun 2027 | −$0.81 | — | — |
| Mar 2027 | −$0.86 | — | — |
| Dec 2026 | −$1.13 | — | — |
| Nov 2026 | −$1.06 | — | — |
| Aug 2026 | −$1.19 | −$0.94 | +21.0% |
| May 2026 | −$1.19 | −$1.28 | −7.6% |
| Feb 2026 | −$1.15 | −$1.37 | −19.1% |
| Nov 2025 | −$1.26 | −$1.17 | +7.1% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Oct 2016 | |||
| Mar 2016 | |||
| Dec 2015 | |||
| Sep 2015 | |||
| Jun 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.74 | — | — | $32.6M | — | — | — |
| Sep 2027 | −$0.76 | — | — | $28.4M | — | — | — |
| Jun 2027 | −$0.81 | — | — | $20.4M | — | — | — |
| Mar 2027 | −$0.86 | — | — | $17.7M | — | — | — |
| Dec 2026 | −$1.13 | — | — | $14.4M | — | — | — |
| Nov 9, 2026 | −$1.06 | — | — | $14.6M | — | — | — |
| Aug 3, 2026 | −$1.19 | −$0.94 | +21.0% | $7.4M | $10.2M | +36.7% | +7.1% |
| May 4, 2026 | −$1.19 | −$1.28 | −7.6% | $6.1M | $1.5M | −76.0% | +3.8% |
| Feb 12, 2026 | −$1.15 | −$1.37 | −19.1% | $4.7M | $864.0K | −81.7% | +8.5% |
| Nov 10, 2025 | −$1.26 | −$1.17 | +7.1% | $9.1M | $889.0K | −90.3% | −1.0% |
| Aug 5, 2025 | |||||||
| May 6, 2025 | |||||||
| Feb 11, 2025 | |||||||
| Nov 5, 2024 | |||||||
| Aug 5, 2024 | |||||||
| May 8, 2024 | |||||||
| Feb 21, 2024 | |||||||
| Nov 6, 2023 | |||||||
| Aug 7, 2023 | |||||||
| May 8, 2023 | |||||||
| Feb 21, 2023 | |||||||
| Nov 1, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 9, 2022 | |||||||
| Feb 15, 2022 | |||||||
| Nov 3, 2021 | |||||||
| Jul 29, 2021 | |||||||
| Apr 27, 2021 | |||||||
| Feb 16, 2021 | |||||||
| Oct 28, 2020 | |||||||
| Jul 27, 2020 | |||||||
| Apr 28, 2020 | |||||||
| Feb 12, 2020 | |||||||
| Oct 28, 2019 | |||||||
| Jul 29, 2019 | |||||||
| Apr 29, 2019 | |||||||
| Feb 25, 2019 | |||||||
| Nov 7, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 8, 2018 | |||||||
| Mar 8, 2018 | |||||||
| Nov 8, 2017 | |||||||
| Aug 10, 2017 | |||||||
| May 11, 2017 | |||||||
| Mar 10, 2017 | |||||||
| Nov 22, 2016 | |||||||
| Oct 19, 2016 | |||||||
| Mar 31, 2016 | |||||||
| Dec 31, 2015 | |||||||
| Sep 30, 2015 | |||||||
| Jun 30, 2015 |